

Stephen K Tying

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6114501/publications.pdf>

Version: 2024-02-01

87
papers

3,291
citations

186209

28
h-index

155592

55
g-index

88
all docs

88
docs citations

88
times ranked

3154
citing authors

#	ARTICLE	IF	CITATIONS
1	Human papillomavirus 57 positivity in periungual squamous cell carcinoma eradicated by topical tirbanibulin. <i>JAAD Case Reports</i> , 2022, 22, 58-59.	0.4	1
2	Tirbanibulin 1% ointment eradicates HPV (+) vulvar high-grade squamous intraepithelial lesion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
3	Reactivation of Chagas disease in organ transplant recipients: Panniculitis as the only skin manifestation in a three case series. <i>Australasian Journal of Dermatology</i> , 2021, 62, 231-232.	0.4	2
4	Penile nodules. <i>International Journal of Dermatology</i> , 2021, 60, e103.	0.5	0
5	Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. <i>New England Journal of Medicine</i> , 2021, 384, 512-520.	13.9	82
6	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930.	0.6	11
7	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106.	1.3	19
8	Tobacco regulation as a paradigm for advancing regulatory science in dermatology. <i>International Journal of Dermatology</i> , 2018, 57, 368-370.	0.5	0
9	Human polyomavirus 7 (HPV7) associated dermatoses: novel molecular mechanism driven by viral activation of 4E-BP1 and MEK-ERK1/2. <i>International Journal of Dermatology</i> , 2018, 58, 383-387.	0.5	4
10	High-risk mucosal HPV types associated with squamous cell carcinoma on the nose tip in an immunocompetent young man. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 716-718.	0.5	4
11	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.4	57
12	BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. <i>British Journal of Dermatology</i> , 2017, 177, 914-923.	1.4	29
13	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2017, 376, 1551-1560.	13.9	413
14	A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis. <i>Skin Therapy Letter</i> , 2017, 22, 1-6.	0.3	2
15	Dupilumab for Moderate-to-Severe Atopic Dermatitis. <i>Skin Therapy Letter</i> , 2017, 22, 1-4.	0.3	15
16	Small T antigen of the HPV7 associated polyomavirus activates factors implicated in the MAPK pathway. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1061-1062.	1.3	20
17	Molecular insight into the viral biology and clinical features of trichodysplasia spinulosa. <i>British Journal of Dermatology</i> , 2016, 174, 490-498.	1.4	24
18	Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. <i>Archives of Dermatological Research</i> , 2016, 308, 357-365.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 841-850.	0.6	135
20	Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 34-41.	0.1	19
21	A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis. <i>Skin Therapy Letter</i> , 2016, 21, 1-6.	0.3	15
22	Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. <i>BMC Dermatology</i> , 2015, 15, 8.	2.1	33
23	Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2624-2634.	3.2	25
24	Vaccination of older adults against herpes zoster is safe and effective. <i>Evidence-Based Medicine</i> , 2013, 18, e43-e43.	0.6	1
25	Famciclovir for recurrent genital herpes. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 557-563.	0.4	0
26	Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2007, 143, 719-26.	1.7	285
27	HPV Typing in Brazilian Patients with Epidermodysplasia Verruciformis: High Prevalence of EV-HPV 25. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 110-5.	0.6	25
28	HPV Typing in Brazilian Patients with Epidermodysplasia Verruciformis: High Prevalence of EV-HPV 25. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 110-115.	0.6	37
29	Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 449-454.	0.6	14
30	Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, S17-S23.	0.7	47
31	Molluscum contagiosum: the importance of early diagnosis and treatment. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, S12-S16.	0.7	64
32	Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and other Viral Infections. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 372-381.	0.6	7
33	Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 449-454.	0.6	20
34	Future Role of Large Neutral Amino Acids in Transport of Phenylalanine Into the Brain. <i>Pediatrics</i> , 2003, 112, 1570-1574.	1.0	47
35	Valacyclovir for Herpes Simplex Virus Infection: Long-Term Safety and Sustained Efficacy after 20 Years' Experience with Acyclovir. <i>Journal of Infectious Diseases</i> , 2002, 186, S40-S46.	1.9	141
36	Imiquimod; an international update on therapeutic uses in dermatology. <i>International Journal of Dermatology</i> , 2002, 41, 810-816.	0.5	46

#	ARTICLE	IF	CITATIONS
37	A Randomized, Double-Blind Trial of Famciclovir Versus Acyclovir for the Treatment of Localized Dermatomal Herpes Zoster in Immunocompromised Patients. <i>Cancer Investigation</i> , 2001, 19, 13-22.	0.6	79
38	Human Papillomavirus, Smoking, and Cancer. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 323-328.	0.6	23
39	Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 43-60.	0.6	67
40	Reduction of Postherpetic Neuralgia in Herpes Zoster. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 409-416.	0.6	7
41	Zinc- β -glycoprotein hinders cell proliferation and reduces cdc2 expression. <i>Journal of Cellular Biochemistry</i> , 2001, 81, 162-169.	1.2	31
42	Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. <i>Journal of Gene Medicine</i> , 2000, 2, 165-175.	1.4	123
43	Response of keratinocytes from normal and psoriatic epidermis to interferon- β differs in the expression of zinc- β -glycoprotein and cathepsin D. <i>FASEB Journal</i> , 2000, 14, 565-571.	0.2	55
44	Antiviral Therapy for Herpes Zoster: Randomized, Controlled Clinical Trial of Valacyclovir and Famciclovir Therapy in Immunocompetent Patients 50 Years and Older. <i>Archives of Family Medicine</i> , 2000, 9, 863-869.	1.5	207
45	Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. <i>Journal of Gene Medicine</i> , 2000, 2, 165-175.	1.4	5
46	Famciclovir and Postherpetic Neuralgia. <i>Annals of Internal Medicine</i> , 1999, 131, 712.	2.0	0
47	Genital Warts and Their Treatment. <i>Clinical Infectious Diseases</i> , 1999, 28, S37-S56.	2.9	92
48	Characterization of zinc- β -glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line. , 1999, 75, 160-169.		16
49	Methylenetetrahydrofolate reductase (MTHFR): The incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. , 1999, 86, 380-384.		61
50	Novel missense mutation (Y231C) in a Turkish patient with Canavan disease. , 1999, 87, 273-275.		11
51	A Guide to Immunotherapy of Genital Warts. <i>BioDrugs</i> , 1999, 11, 319-332.	2.2	21
52	Combined Epstein-Barr Virus and Human Papillomavirus Infection in Nasopharyngeal Carcinoma. <i>Laryngoscope</i> , 1998, 108, 362-367.	1.1	42
53	Malignant Transformation of Recurrent Respiratory Papillomatosis Associated With Integrated Human Papillomavirus Type 11 DNA and Mutation of p53. <i>Laryngoscope</i> , 1998, 108, 735-740.	1.1	129
54	Differentiation and cathepsin D expression in human oral tumors. <i>Laryngoscope</i> , 1998, 108, 1234-1237.	1.1	6

#	ARTICLE	IF	CITATIONS
55	High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. <i>Journal of Medical Virology</i> , 1998, 54, 69-73.	2.5	17
56	Induction by interferon- β of its receptor varies with epithelial differentiation and cell type. <i>Archives of Dermatological Research</i> , 1998, 290, 331-334.	1.1	7
57	Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor. <i>Annals of Surgical Oncology</i> , 1998, 5, 642-649.	0.7	5
58	Status of Cytokine and Antigen Presentation Genes in Merkel Cell Carcinoma of the Skin. <i>Journal of Cutaneous Medicine and Surgery</i> , 1998, 2, 138-141.	0.6	4
59	Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 1180-1184.	0.5	14
60	The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 563-573.	2.3	25
61	Antiviral Therapy of Acute Herpes Zoster in Older Patients. <i>Drugs and Aging</i> , 1996, 8, 97-112.	1.3	27
62	Human papillomavirus is associated with monoclonal gammopathies of unknown significance. <i>Journal of Biomedical Science</i> , 1996, 3, 319-322.	2.6	5
63	Efficacy of famciclovir in the treatment of herpes zoster. <i>Seminars in Dermatology</i> , 1996, 15, 27-31.	0.6	15
64	Herpesvirus-like DNA sequences in classic Kaposi's Sarcomas. <i>Journal of Medical Virology</i> , 1995, 47, 179-183.	2.5	42
65	ANTIVIRAL AGENTS IN DERMATOLOGY: CURRENT STATUS AND FUTURE PROSPECTS. <i>International Journal of Dermatology</i> , 1995, 34, 597-606.	0.5	13
66	Major Therapeutic Uses of Interferons. <i>BioDrugs</i> , 1995, 3, 27-87.	0.7	39
67	Cutaneous and Subcutaneous Endometriosis. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1994, 20, 693-695.	0.8	101
68	Evidence for the production and action of interleukin-10 in pituitary cells. <i>Cellular and Molecular Neurobiology</i> , 1994, 14, 59-69.	1.7	31
69	PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS OF VARICELLA ZOSTER VIRUS INFECTIONS. <i>International Journal of Dermatology</i> , 1994, 33, 227-232.	0.5	18
70	NONSUNLIGHT RISK FACTORS FOR MALIGNANT MELANOMA PART II: IMMUNITY, GENETICS, AND WORKPLACE PREVENTION. <i>International Journal of Dermatology</i> , 1994, 33, 462-467.	0.5	7
71	NONSUNLIGHT RISK FACTORS FOR MALIGNANT MELANOMA PART I: CHEMICAL AGENTS, PHYSICAL CONDITIONS, AND OCCUPATION. <i>International Journal of Dermatology</i> , 1994, 33, 398-406.	0.5	23
72	Detection of human papillomavirus L1 protein in condylomata acuminata from adults with defects in cell-mediated immunity. <i>Journal of Medical Virology</i> , 1993, 41, 79-84.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Squamous Cell Carcinoma Secondary to Recessive Dystrophic Epidermolysis Bullosa: A Report of 4 Patients with 17 Primary Cutaneous Malignancies. The Journal of Dermatologic Surgery and Oncology, 1992, 18, 301-305.	0.8	16
74	STRONGYLOIDES HYPERINFECTION PRESENTING WITH PETECHIAE AND PURPURA. International Journal of Dermatology, 1992, 31, 169-171.	0.5	23
75	STRONGYLOIDES STERCORALIS HYPERINFECTION. International Journal of Dermatology, 1992, 31, 160-164.	0.5	12
76	Human papillomavirus 16 exhibits a similar integration pattern in primary squamous cell carcinoma of the penis and in its metastasis. Cancer, 1992, 70, 2143-2148.	2.0	20
77	Natural history of varicella zoster virus. Seminars in Dermatology, 1992, 11, 211-7.	0.6	27
78	Prognosis and Treatment of Advanced Squamous Cell Carcinoma Secondary to Epidermodysplasia Verruciformis: A Worldwide Analysis of 11 Patients. The Journal of Dermatologic Surgery and Oncology, 1991, 17, 237-240.	0.8	16
79	Lepromatous Leprosy Mimicking Porphyria Cutanea Tarda. International Journal of Dermatology, 1991, 30, 578-580.	0.5	2
80	Papular protothecosis of the chest. Immunologic evaluation and treatment with a combination of oral tetracycline and topical amphotericin B. Archives of Dermatology, 1989, 125, 1249-1252.	1.7	20
81	Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Archives of Dermatology, 1989, 125, 797-800.	1.7	4
82	Erythema gyratum repens a cutaneous marker of malignancy. Cancer, 1988, 62, 548-550.	2.0	30
83	Treatment of condyloma acuminatum with interferon. Seminars in Oncology, 1988, 15, 35-40.	0.8	1
84	Activation of natural killer cell function during interferon-alpha treatment of patients with condyloma acuminatum is predictive of clinical response. Journal of Biological Regulators and Homeostatic Agents, 1988, 2, 63-6.	0.7	3
85	Development of verrucous plaques and gross hematuria in advanced cutaneous T-cell lymphoma. Archives of Dermatology, 1988, 124, 655-7.	1.7	0
86	Antitumor Actions of Interferons.. International Journal of Dermatology, 1987, 26, 549-556.	0.5	19
87	Direct cytolysis by partially-purified preparations of immune interferon. International Journal of Cancer, 1982, 30, 59-64.	2.3	73